Lpath Inc. moved quickly to digest the disappointment that partner Pfizer Inc. plans to divest “a number of” its ophthalmology R&D assets, including its exclusive option for a global license to develop and commercialize Lpath’s wet age-related macular degeneration (AMD) candidate Isonep. Scott Pancoast, Lpath’s president and CEO, said the path forward for Isonep is a choice between regaining rights to the compound, currently in a four-arm Phase II study, or having them reassigned to a third-party bidder – either of which offers potential upside.